Table 3: Patient demographics and clinical characteristics for those who received GC or MVAC neoadjuvant chemotherapy.

GC
(%)
MVAC
(%)
value

Gender0.10
 Male31 (76%)28 (90%)
 Female10 (24%)3 (10%)
Age0.01
 <6013 (31%)14 (45%)
 60–6914 (34%)16 (51%)
 >7014 (34%)1 (3%)
Race0.47
 Caucasian35 (85%)29 (94%)
 Other6 (15%)2 (6%)
Complete TURBT0.72
 Yes16 (41%)14 (45%)
 No22 (59%)15 (55%)
Cardiac disease0.25
 Yes8 (20%)3 (10%)
 No33 (80%)28 (90%)
Creatinine0.24
 ≤1.028 (68%)17 (53%)
 >1.013 (32%)14 (47%)
Clinical T-stage0.52
 T223 (56%)14 (45%)
 T311 (27%)9 (29%)
 T47 (17%)8 (26%)
Pathologic T-stage0.45
 pT012 (29%)7 (23%)
 pTa0 (0%)2 (6%)
 pTIS8 (20%)2 (6%)
 pT13 (7%)3 (10%)
 pT24 (10%)6 (20%)
 pT3a8 (20%)6 (20%)
 pT3b2 (5%)2 (7%)
 pT44 (10%)2 (7%)
Pathologic N-stage0.09
 N035 (85%)22 (71%)
 N16 (15%)9 (28%)